Research location
Wels
Austria
Advertisement
Research activity in Wels
AustriaCureCurrent currently publishes aggregate city-level research activity for this location: 123 trials and 123 site observations.
The map is centered on registry-derived city coordinates. Circle size reflects published trial activity.
Below are current trials with one or more ClinicalTrials.gov site observations in this city. Results are paginated 50 per page, with recruiting studies shown first.
Trials with sites in Wels
123 linked trials · page 1 of 3A Study to Investigate CV Outcomes With Elecoglipron Compared With Placebo in Adult Participants With HFpEF or HFmrEFNCT07761117 · 2026-08-24 · 1 site observation
RECRUITING
A Study to Evaluate Patient-Reported Satisfaction, Effectiveness, and Safety of Atezolizumab in Participants Treated in Routine Clinical PracticeNCT07284121 · 2025-07-15 · 1 site observation
RECRUITING
Diagnostic HER2DX-guided Treatment for Patients wIth Early-stage HER2-positive Breast CancerNCT06446882 · 2024-10-11 · 1 site observation
RECRUITING
A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast CancerNCT06435429 · 2024-08-13 · 1 site observation
RECRUITING
Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic AlterationsNCT06357533 · 2024-04-11 · 1 site observation
RECRUITING
A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)NCT05920356 · 2023-11-16 · 1 site observation
RECRUITING
DESTINY Breast Respond HER2-(Ultra)Low EuropeNCT05945732 · 2023-10-24 · 1 site observation
RECRUITING
A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine TherapyNCT05774951 · 2023-03-31 · 1 site observation
RECRUITING
The "Global Paradise System" RegistryNCT05027685 · 2022-01-13 · 1 site observation
RECRUITING
OP-1250 (Palazestrant) vs. Standard of Care for the Treatment of ER+/HER2- Advanced Breast CancerNCT06016738 · 2023-11-16 · 1 site observation
ACTIVE_NOT_RECRUITING
A Global Study of Volrustomig (MEDI5752) Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy for Participants With Metastatic Non-small Cell Lung Cancer.NCT05984277 · 2023-10-24 · 1 site observation
ACTIVE_NOT_RECRUITING
An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2)NCT05952557 · 2023-10-05 · 1 site observation
ACTIVE_NOT_RECRUITING
A Study for the Participants With Metastatic Hormone Sensitive Prostate Cancer (mHSPC) Treated With Androgen Deprivation Therapy (ADT) Plus Apalutamide or EnzalutamideNCT05901649 · 2023-07-05 · 1 site observation
COMPLETED
Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Patients With Hormone Receptor-positive/Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) Metastatic Breast Cancer Who Have Received Endocrine TherapyNCT05840211 · 2023-05-08 · 1 site observation
ACTIVE_NOT_RECRUITING
Gedatolisib Plus Fulvestrant With or Without Palbociclib vs Standard-of-Care for the Treatment of Patients With Advanced or Metastatic HR+/HER2- Breast Cancer (VIKTORIA-1)NCT05501886 · 2022-12-08 · 1 site observation
ACTIVE_NOT_RECRUITING
Study of Efficacy and Safety of JDQ443 Single-agent as First-line Treatment for Patients With Locally Advanced or Metastatic KRAS G12C- Mutated Non-small Cell Lung Cancer With a PD-L1 Expression < 1% or a PD-L1 Expression ≥ 1% and an STK11 Co-mutation.NCT05445843 · 2022-12-06 · 1 site observation
ACTIVE_NOT_RECRUITING
Zimberelimab and Domvanalimab in Combination With Chemotherapy Versus Pembrolizumab With Chemotherapy in Patients With Untreated Metastatic Non-Small Cell Lung CancerNCT05502237 · 2022-10-12 · 1 site observation
ACTIVE_NOT_RECRUITING
HERTHENA-Lung02: A Study of Patritumab Deruxtecan Versus Platinum-based Chemotherapy in Metastatic or Locally Advanced EGFRm NSCLC After Failure of EGFR TKI TherapyNCT05338970 · 2022-07-08 · 1 site observation
ACTIVE_NOT_RECRUITING
A Study Evaluating the Efficacy and Safety of Adjuvant Giredestrant Compared With Physician's Choice of Adjuvant Endocrine Monotherapy in Participants With Estrogen Receptor-Positive, HER2-Negative Early Breast Cancer (lidERA Breast Cancer)NCT04961996 · 2021-08-27 · 1 site observation
ACTIVE_NOT_RECRUITING
A 52-week, Placebo-controlled Study to Evaluate the Efficacy and Safety of 2 Doses of CHF6001 DPI (Tanimilast), as add-on to Maintenance Triple Therapy in Subjects With COPD and Chronic Bronchitis (PILASTER)NCT04636801 · 2021-07-14 · 1 site observation
TERMINATED
A 52-week, Placebo- and Active- Controlled (Roflumilast, Daliresp® 500µg) Study to Evaluate the Efficacy and Safety of Two Doses of CHF6001 DPI (Tanimilast) as add-on to Maintenance Triple Therapy in Subjects With COPD and Chronic Bronchitis. (PILLAR)NCT04636814 · 2021-07-12 · 1 site observation
TERMINATED
Sacituzumab Govitecan in Primary HER2-negative Breast CancerNCT04595565 · 2020-10-28 · 1 site observation
ACTIVE_NOT_RECRUITING
A Study to Evaluate Safety and Efficacy of APO-2 at Three Different Doses in Patients With Diabetic Foot UlcerNCT04277598 · 2020-10-09 · 1 site observation
COMPLETED
A Study Investigating the Outcomes and Safety of Atezolizumab Under Real-World Conditions in Patients Treated in Routine Clinical PracticeNCT03782207 · 2019-02-07 · 1 site observation
COMPLETED
Trastuzumab Deruxtecan (DS-8201a) Versus Investigator's Choice for HER2-low Breast Cancer That Has Spread or Cannot be Surgically Removed [DESTINY-Breast04]NCT03734029 · 2018-12-27 · 1 site observation
COMPLETED
Blood Pressure Control in ESH Excellence CentresNCT04295434 · 2018-10-01 · 1 site observation
UNKNOWN
Tailored Axillary Surgery With or Without Axillary Lymph Node Dissection Followed by Radiotherapy in Patients With Clinically Node-positive Breast Cancer (TAXIS)NCT03513614 · 2018-08-07 · 1 site observation
ACTIVE_NOT_RECRUITING
A Study Comparing Atezolizumab (Anti PD-L1 Antibody) In Combination With Adjuvant Anthracycline/Taxane-Based Chemotherapy Versus Chemotherapy Alone In Patients With Operable Triple-Negative Breast CancerNCT03498716 · 2018-08-02 · 1 site observation
TERMINATED
An Immuno-Therapy Study of Experimental Medication BMS-986205 Given With Nivolumab With or Without Chemotherapy Compared to Chemotherapy in Participants With Previously Untreated Stage IV or Recurrent Non-Small Cell Lung CancerNCT03417037 · 2018-05-24 · 1 site observation
WITHDRAWN
54135419SUI3002: A Study to Evaluate the Efficacy and Safety of Intranasal Esketamine in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Symptoms of Major Depressive Disorder, Including Suicidal Ideation, in Adult Participants Assessed to be at Imminent Risk for SuicideNCT03097133 · 2017-06-15 · 1 site observation
COMPLETED
Genomic Testing and Resulting Medical DecisionsNCT03301493 · 2017-03-30 · 1 site observation
COMPLETED
Efficacy and Safety of Lanreotide Autogel/ Depot 120 mg vs. Placebo in Subjects With Lung Neuroendocrine TumoursNCT02683941 · 2017-03-06 · 1 site observation
TERMINATED
Screening for the Transthyretin-Related Familial Amyloidotic Polyneuropathy (TTR FAP)NCT01705626 · 2016-12-01 · 1 site observation
COMPLETED
A Study of Atezolizumab in Combination With Carboplatin or Cisplatin + Pemetrexed Compared With Carboplatin or Cisplatin + Pemetrexed in Participants Who Are Chemotherapy-Naive and Have Stage IV Non-Squamous Non-Small Cell Lung Cancer (NSCLC) (IMpower 132)NCT02657434 · 2016-04-30 · 1 site observation
COMPLETED
Efficacy and Safety of Finerenone in Subjects With Type 2 Diabetes Mellitus and Diabetic Kidney DiseaseNCT02540993 · 2015-09-17 · 1 site observation
COMPLETED
Efficacy and Safety of Finerenone in Subjects With Type 2 Diabetes Mellitus and the Clinical Diagnosis of Diabetic Kidney DiseaseNCT02545049 · 2015-09-17 · 1 site observation
COMPLETED
Effectiveness Study of Nivolumab Compared to Chemotherapy in Patients With Relapsed Small-cell Lung CancerNCT02481830 · 2015-09-14 · 1 site observation
COMPLETED
An Investigational Immuno-therapy Trial of Nivolumab, or Nivolumab Plus Ipilimumab, or Nivolumab Plus Platinum-doublet Chemotherapy, Compared to Platinum Doublet Chemotherapy in Patients With Stage IV Non-Small Cell Lung Cancer (NSCLC)NCT02477826 · 2015-08-05 · 1 site observation
COMPLETED
PALbociclib CoLlaborative Adjuvant StudyNCT02513394 · 2015-08-01 · 1 site observation
ACTIVE_NOT_RECRUITING
SPYRAL HTN-ON MED Study of Renal Denervation With the Symplicity Spyral™ Multi-electrode Renal Denervation SystemNCT02439775 · 2015-07-22 · 1 site observation
COMPLETED
Study to Assess the Efficacy and Safety of PT010 Relative to PT003 and PT009 in Subjects With Moderate to Very Severe COPD (Ethos)NCT02465567 · 2015-06-30 · 1 site observation
COMPLETED
SPYRAL PIVOTAL - SPYRAL HTN-OFF MED StudyNCT02439749 · 2015-06-01 · 1 site observation
COMPLETED
A Study of Atezolizumab in Combination With Carboplatin Plus (+) Paclitaxel With or Without Bevacizumab Compared With Carboplatin+Paclitaxel+Bevacizumab in Participants With Stage IV Non-Squamous Non-Small Cell Lung Cancer (NSCLC)NCT02366143 · 2015-03-31 · 1 site observation
COMPLETED
Sentus QP - Extended CRT Evaluation With Quadripolar Left Ventricular LeadsNCT02290028 · 2014-12-16 · 1 site observation
TERMINATED
A Study of Neoadjuvant Letrozole + Taselisib Versus Letrozole + Placebo in Post-Menopausal Women With Breast Cancer (LORELEI)NCT02273973 · 2014-11-12 · 1 site observation
COMPLETED
Prevention of Symptomatic Skeletal Events With Denosumab Administered Every 4 Weeks Versus Every 12 WeeksNCT02051218 · 2014-07-16 · 1 site observation
ACTIVE_NOT_RECRUITING
Benralizumab Efficacy in Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD) With Exacerbation HistoryNCT02138916 · 2014-06-13 · 1 site observation
COMPLETED
Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast CancerNCT02032823 · 2014-04-22 · 1 site observation
ACTIVE_NOT_RECRUITING
An Open-Label, Randomized, Phase 3 Trial of Nivolumab Versus Investigator's Choice Chemotherapy as First-Line Therapy for Stage IV or Recurrent PD-L1+ Non-Small Cell Lung Cancer (CheckMate 026)NCT02041533 · 2014-03-27 · 1 site observation
COMPLETED
Study to Evaluate the Efficacy and Safety of Glycopyrronium or Indacaterol Maleate and Glycopyrronium Bromide Fixed-dose Combination Regarding Symptoms and Health Status in Patients With Moderate COPD Switching From Treatment With Any Standard COPD RegimenNCT01985334 · 2014-02-14 · 1 site observation
COMPLETED
Advertisement
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.